instruction:
Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.
question:
Paragraph: Shares of the company traded marginally down at $132.47, after having closed up 1.7% on Monday. (bit.ly/2ZkZGze)    J&J said that the FTC had issued a “civil investigative demand,” or CID, the equivalent of a subpoena to determine if the contracting practices were legal. Pfizer Inc filed a lawsuit against J&J in 2017, saying its rival’s contracts with health insurers for blockbuster rheumatoid arthritis drug, Remicade, were anticompetitive and aimed at blocking sales of Pfizer’s biosimilar called Inflectra. Pfizer said in the lawsuit that J&J had contracted with many insurers to give discounts in exchange for giving preference to Remicade, and to only pay for Inflectra in cases where Remicade proved to be ineffective. Inflectra was approved in 2016 while Remicade went on the market in 1998. Remicade is an infused treatment for chronic autoimmune disorders and costs about $4,000 per dose, or $26,000 a year, Pfizer said in the lawsuit. J&J has denied any wrongdoing and is fighting the Pfizer lawsuit. Pfizer said in a statement that it had received a CID in June. “As Pfizer’s complaint alleges, J&J’s unlawful conduct is designed to prevent Inflectra from being able to compete on its primary point of differentiation – price. Today, Inflectra has an average selling price (ASP) that is more than 22% lower than Remicade,” the company said in a statement. “Despite these facts, J&J has not lost substantial volume or share of sales – counter to what should occur in a competitive market.”  Biosimilars are intended to be lower-cost alternatives to expensive biotech medicines. But since they are made from living cells and it is not possible to make an exact copy of the branded medicine, they are not automatically substituted for the existing branded drug the way a generic drug would be. The drugs treat ailments like rheumatoid arthritis, Crohn’s disease and ulcerative colitis. Claim: J&J says FTC probing efforts to protect arthritis drug Remicade.
answer:
The Federal Trade Commission issued civil subpoenas to Johnson and Johnson in June as part of an investigation into whether contracting practices for its blockbuster rheumatoid arthritis drug, Remicade, violated antitrust laws, the company said in a regulatory filing on Monday.


question:
Paragraph: "Gov. Andrew M. Cuomo says women in New York state don’t have to worry about new Trump administration rules ending a federal requirement that employers must include birth control coverage in their health insurance plans. The new rules exempt employers from the Obama-era mandate if they have religious or moral reservations to the coverage. But Cuomo said contraception will still be covered in New York state. ""This year, we ensured that whatever happens at the federal level, women in our state will continue to have cost-free access to reproductive health care,"" Cuomo said in a statement. States can set certain insurance standards beyond what the federal government requires. New York state told insurance companies in January they are required to cover birth control and abortion services. That condition still stands, but is Cuomo right that women in New York state are not affected by Trump’s decision? Limits to state regulation State regulations, like the one from January, do not apply to all plans. The state Department of Financial Services regulates everything sold on the state health exchange, called New York State of Health. That includes plans sold to individuals and companies with 100 or fewer employees. The agency says the state’s birth control mandate covers 1.35 million residents in those plans. Health care offered through companies with more than 100 employees is more complicated. Companies that go the traditional route of buying health coverage through an insurance carrier must adhere to the rules. About 2.5 million people in that category are covered by the state’s birth control mandate. But companies that are self-insured, where the employer assumes a large part of the costs, are not regulated by the state, meaning they need not adhere to the state's birth control mandate. About 60 percent of private sector workers in the U.S. who get their health coverage through an employer were enrolled in a self-insured plan in 2015. That’s up from 46 percent in 1996, according to research from the Employee Benefit Research Institute. In New York state, about 54 percent of private sector employees who get health insurance through their employer had a self-insured plan last year, according to the federal Agency for Healthcare Research and Quality. The option is most popular for companies with at least 1,000 employees. Eighty percent of private sector employees at companies that size in New York state are enrolled in a self-insured plan. What about public health insurance? The federal government sets the baseline for what services are covered under Medicaid. Government workers are covered under state regulation, but Medicaid and Medicare enrollees are not.States can add to that list. The list of services covered by Medicaid in New York state goes well beyond the federal standard. New York is one of multiple states where Medicaid covers birth control and abortion services. About a third of the state’s population alone is on Medicaid. Our ruling Cuomo said women in New York state ""will continue to have cost-free access to reproductive health care"" because of an action the state took earlier this year. But not every woman is in an insurance plan regulated by the state. It’s possible a self-insured large employer in New York state could apply for an exemption from the federal birth control mandate. If granted the exemption, the company would not have to provide health coverage for birth control to its employees. Those exemptions are not expected to be widespread, but they are possible. Cuomo’s statement needs clarification." Claim: Women in our state will continue to have cost-free access to reproductive health care
answer:
"Cuomo said women in New York state ""will continue to have cost-free access to reproductive health care"" because of an action the state took earlier this year. But not every woman is in an insurance plan regulated by the state. It’s possible a self-insured large employer in New York state could apply for an exemption from the federal birth control mandate. If granted the exemption, the company would not have to provide health coverage for birth control to its employees. Those exemptions are not expected to be widespread, but they are possible. Cuomo’s statement needs clarification."


question:
Paragraph: Biotechnology company Alkermes said earlier in the day that  it expected Lilly to drop out of their program to develop an  inhaled insulin treatment for diabetes, sending Alkermes shares  down more than 9 percent. Lilly’s decision marks the third setback in recent months  for inhaled insulin formulations, once deemed potential  blockbuster products because of their greater convenience than  standard injectable insulin. Cambridge, Massachusetts-based Alkermes, which makes the  alcohol addiction drug Vivitrol, said Lilly has the right to  terminate its license to the inhaled treatment, Air Insulin, at  its discretion. “While Lilly may elect not to commercialize Air Insulin,  Alkermes believes that the phase 3 safety and efficacy trials  should be completed,” Alkermes said in a statement. After Lilly’s announcement, the company said it was  evaluating the impact of the termination, which will become  effective in 90 days. Indianapolis-based Lilly said its decision was not due to  safety concerns, “but rather was a result of increasing  uncertainties in the regulatory environment, and a thorough  evaluation of the evolving commercial and clinical potential of  the product compared to existing medical therapies.”    Lilly Chief Operating Officer John Lechleiter said in a  statement that the company is beginning the process of halting  ongoing clinical studies. Lilly said it will record a first-quarter 2008 charge of  around $90 million to $120 million, or 5 cents to 7 cents per  share. The company said its adjusted earnings per share outlook  remains unchanged at $3.85 to $4.00, while net earnings will  range from $3.73 to $3.90. Lilly’s action comes just five months after Pfizer Inc  abandoned Exubera, the first approved inhaled form of insulin,  and returned rights to the product to longtime partner Nektar  Therapeutics. Exubera had dismal sales because patients were turned off  by the clumsy device used to administer the powdered insulin  and because doctors were concerned by the drug’s tendency to  slightly impair lung function. Alkermes Chairman Richard Pops, in an interview with  Reuters in October, said Air Insulin may have similar effects  on lung function. “We’re assuming that pulmonary insulins in that regard are  all pretty much the same,” he said, although a conclusive  picture of Air Insulin’s safety will not emerge until two-year  safety trials of the product end later this year. A second setback for inhaled insulin came in January, when  Novo Nordisk said it was halting development of its AERx  product, meant to deliver inhaled droplets. The Danish  drugmaker said AERx did not have adequate sales potential,  given the limited commercial success seen with Exubera. Morgan Stanley analyst Jami Rubin said on Friday Lilly’s  abandonment of AIR Insulin made good business sense. “We are not (at) all surprised, and have never been strong  advocates of the pulmonary insulin agents, following the poor  launch and ultimate demise of Pfizer and Nektar’s Exubera and  Novo Nordisk’s termination of its AERx program,” Rubin said in  a research note. Rubin said Alkermes, known for its drug-delivery  technology, is unlikely to continue development of Air Insulin  without Lilly, “given that this represents the third  termination of a pulmonary insulin drug.”    But she said the sharp drop in Alkermes shares represented  a buying opportunity for investors because Air Insulin had only  paltry sales potential. She said investors should be focused instead on another  product Alkermes is developing with Lilly: a long-acting  formulation of Lilly’s Byetta diabetes treatment called Byetta    “We estimate that Byetta LAR could be worth $11 to $12 for  the (Alkermes) stock,” Ryan said. Alkermes shares fell $1.14 to close at $11.26 on Nasdaq. Lilly, a far larger company with an array of big-selling  products, rose 2 cents to end at $49.70 on the New York Stock  Exchange, and was slightly lower at $49.67 in after-hours  trading. Claim: Eli Lilly drops inhaled insulin program.
answer:

Eli Lilly & Co said on Friday it will  terminate development of an inhaled insulin treatment for  diabetes, which it was conducting in partnership with Alkermes  Inc, after deciding that product’s commercial potential was not  strong.